Bictegravir-Tenofovir alafenamide-Emtricitabine Biktarvy
Darunavir-Cobicistat-Tenofovir alafenamide-Emtricitabine Symtuza
Dolutegravir-Abacavir-Lamivudine Triumeq
Dolutegravir-Lamivudine Dovato
Dolutegravir-Rilpivirine Juluca
Doravirine-Tenofovir DF-Lamivudine Delstrigo
Efavirenz-Tenofovir DF-Emtricitabine Atripla
Elvitegravir-Cobicistat-Tenofovir alafenamide-Emtricitabine Genvoya
Elvitegravir-Cobicistat-Tenofovir DF-Emtricitabine Stribild
Rilpivirine-Tenofovir alafenamide-Emtricitabine Odefsey
Rilpivirine-Tenofovir DF-Emtricitabine Complera
Fostemsavir Rukobia
Ibalizumab Trogarzo
Maraviroc Selzentry
Dolutegravir Tivicay
Raltegravir Isentress
Tenofovir alafenamide-Emtricitabine Descovy
Tenofovir DF-Emtricitabine Truvada and Multiple Generics
Doravirine Pifeltro
Efavirenz Sustiva
Etravirine Intelence
Rilpivirine EdurantSection Navigation
Section Navigation
- Module 6 Overview
Key Populations - 0%Lesson 1
HIV in Infants and ChildrenActivities- 0%Lesson 2
HIV in Adolescents and Young AdultsActivities- 0%Lesson 3
HIV in WomenActivities- 0%Lesson 4
HIV in Older AdultsActivities- 0%Lesson 5
HIV and CorrectionsLesson 4. HIV in Older Adults
Learning Objective Performance Indicators
- Recognize age-related and HIV-related changes to the immune systems of people 50 years of age and older
- Discuss the interplay of HIV and the aging process within the framework of accelerated and accentuated aging
- List recommendations for antiretroviral therapy management in persons 50 years of age and older.
- Explain expected virologic and immunologic responses to antiretroviral therapy in persons 50 years of age and older.
- Highlight comorbidities that more commonly occur in older adults with HIV
About this Lesson
Learning Objective Performance Indicators
- Recognize age-related and HIV-related changes to the immune systems of people 50 years of age and older
- Discuss the interplay of HIV and the aging process within the framework of accelerated and accentuated aging
- List recommendations for antiretroviral therapy management in persons 50 years of age and older.
- Explain expected virologic and immunologic responses to antiretroviral therapy in persons 50 years of age and older.
- Highlight comorbidities that more commonly occur in older adults with HIV
Activities in this Lesson
- Quick ReferenceHIV in Older Adults Core Concepts
- Background
- Accelerated versus Accentuated Aging
- Epidemiology of HIV in Older Persons
- Screening and Detection of HIV in Older Adults
- Antiretroviral Therapy in the Older Patient with HIV
- Common Comorbid Conditions in Older Persons with HIV
- Life Expectancy, Age of Death, and Advanced Care Planning
- Summary Points
Share by e-mail
Check
-On-
Learning
QuestionsThe Check-on-Learning Questions are short and topic related. They are meant to help you stay on track throughout each lesson and check your understanding of key concepts.You must be signed in to customize your interaction with these questions.
- 0%Lesson 2
Funded by
Health Resources and Services Administration (HRSA)
Created at
University of Washington
An AETC Program
Part of
IDEA Platform
CME provided byUniversity of Alabama Birmingham
CNE approved byOregon Nurses Association
Copyright © 2025 National HIV Curriculum
The Health Resources and Services Administration (HRSA), Department of Health and Human Services (HHS) provided financial support for this website. The award provided 100% of total costs and totaled $1,172,994. The contents are those of the author. They may not reflect the policies of HRSA, HHS, or the U.S. Government.
Since you've received 80% or better on this quiz, you may claim continuing education credit.
You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.
Current Version: nhivc-master-d52d2330-2025-09-05-201745